We are grateful for the strong support from our existing and new investors
Past News ReleasesRSS
New York, NY (Vocus/PRWEB) February 10, 2011
Signet Healthcare Partners, a private equity firm focused on investing in Life Sciences Companies, is pleased to announce the closing of its third investment fund at approximately $129 million. Much of the new fund’s capital is derived from returning investors but also from several new significant industry investors and family offices. The closing of the third fund brings total funds under management to $328 million.
Signet will invest this fund primarily in companies producing generic and specialty pharmaceuticals, biopharmaceuticals, medical devices and other related technology, diagnostics, and research-based companies supporting this industry. Consistent with its predecessor funds, the new fund will invest primarily in commercial-stage companies in the U.S. and Europe. The new fund expects to invest over a four-year period with individual investments in the $6-15 million range.
“We are grateful for the strong support from our existing and new investors,” commented James C. Gale, the founding partner of Signet. “The growth in our funds under management has enabled us to expand our investment team.”
Signet generally serves as lead or co-lead investor in its investments. The transactions, include spinouts from large corporations, restructuring, product launches as well as growth capital for growing Life Sciences businesses. The firm’s Managing Partners are experienced in the industry and include Joyce Erony, Al Hansen and Martin Zeiger; joined by Todd Sone and Samuel Altman.
About Signet Healthcare Partners
Signet Healthcare Partners was founded in 1998 and is comprised of a team that brings over 100 years of collective experience in the biopharmaceutical, medical device, private equity and investment banking businesses. Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor providing growth and expansion capital to commercial stage companies engaged in specialty pharmaceuticals, medical devices and biopharmaceutical services.
# # #